Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms

Therapy‐related myeloid neoplasms (t‐MN) are aggressive malignancies in need of effective therapies. The BCL‐2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t‐MN. We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Mithun Vinod, Chhetri, Rakchha, Dholakia, Ruchita, Kok, Chung H., Gangat, Naseema, Alkhateeb, Hassan B., Al‐Kali, Aref, Patnaik, Mrinal M., Baranwal, Anmol, Greipp, Patricia T., He, Rong, Begna, Kebede H., Tiong, Ing Soo, Wei, Andrew H., Hiwase, Devendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541522/
https://www.ncbi.nlm.nih.gov/pubmed/35560061
http://dx.doi.org/10.1002/ajh.26589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541522/
https://www.ncbi.nlm.nih.gov/pubmed/35560061
http://dx.doi.org/10.1002/ajh.26589

Ejemplares similares